


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-6.74%
-2.03%
-6.62%
-3.96%
+10.21%
HIMS
Hims & Hers
$23.48
Strengths

Earnings are forecast to grow

Expands stock buyback program

Investors confidence is positive
Technical Indicators

5+ Days Down
HIMS Price Performance
$31.69 (-25.91%)
$39.75 (-40.93%)
$53.96 (-56.49%)
$51.31 (-54.24%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Has a weak balance sheet

Revenue increase YoY

Above analyst estimates
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Expands stock buyback program

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
HIMS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
HIMS Street Sentiment is extremely bullish and have positive views on the near-term outlook
HIMS has Low risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Nov 04, 2025
Reiterate
Buy
Canaccord Genuity
What is HIMS current stock price?
What are HIMS stock strengths?
What is HIMS Risk Level?
What is HIMS market cap and volume?
What is HIMS current Stock IQ?
Should I buy HIMS stock right now?
Is HIMS a Strong Buy right now?
What does a 'Strong Buy' rating mean for HIMS?
What does a 'Strong Sell' rating mean for HIMS?
What factors influence HIMS's Stock IQ?
Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-6.74%
-2.03%
-6.62%
-3.96%
+10.21%
HIMS
Hims & Hers
Current Price
$23.48

HIMS Price Performance
$31.69 (-25.91%)
$39.75 (-40.93%)
$53.96 (-56.49%)
$51.31 (-54.24%)
HIMS Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Has a weak balance sheet

Revenue increase YoY

Above analyst estimates
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Expands stock buyback program

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
HIMS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
HIMS Street Sentiment is extremely bullish and have positive views on the near-term outlook
HIMS has Low risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Nov 04, 2025
Reiterate
Buy
Canaccord Genuity
HIMS Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Expands stock buyback program

Investors confidence is positive
Technical Indicators

5+ Days Down
HIMS Latest Analysis
Novo Nordisk says it will take legal action after Hims & Hers reveals $49 copy of Wegovy pill. Hims said it would sell a copy of the newly launched weight loss pill for $49 far less than the $149 Novo sells the branded pill for.
Thu Feb 5, 2026
Hims & Hers Launches Compounded Version Of Wegovy Novo Nordisk Threatens Legal Action. On Thursday HIMS) announced Thursday an specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as ) Starting today eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month.The new Compounded Semaglutide Pill is formulated to protect the active ingredient d
Thu Feb 5, 2026
Hims & Hers Health Stock Rises 7% Over Expansion Of Personalized Weight Loss Portfolio . (RTTNews) - Stock of Hims & Hers Health Inc. (HIMS) is climbing around 7 percent on Thursday morning trading over the announcement of an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pills starting at $49 per month.
Thu Feb 5, 2026
Hims & Hers Scores A Cancer Deal With Grail But Shares Reverse Lower. The former stock market darling briefly shined Wednesday. But shares drew back recently.The post Hims &. Hers Scores A Cancer Deal With Grail But Shares Reverse Lower appeared first on Investor'.s Business Daily.
Wed Feb 4, 2026
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering. Hims &. Hers (NYSE: HIMS) announced today the launch of an early detection cancer test bringing more value to its lab business. This is another product launch that isnt about pushing pills or slotting into the existing insurance ecosystem. its fundamentally disruptive to th
Wed Feb 4, 2026
Hims & Hers Pops After Scoring A Cancer-Screening Deal With Grail. Hims stock popped Wednesday after the telehealth giant said it will begin selling Grails multi-cancer detection test.The post Hims &. Hers Pops After Scoring A Cancer-Screening Deal With Grail appeared first on Investor'.s Business Daily.
Wed Feb 4, 2026
Hims & Hers stock rises after launching multi-cancer detection test.
Wed Feb 4, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
HIMS Stock trends
HIMS Stock performance
HIMS Stock analysis
HIMS investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.